Channel for the Professional Oncology & Hematology Communities. Follow us for congress news, interviews & insightful updates. Guidelines:e.lilly/3XKThyc
Joined May 2022
- Tweets 408
- Following 38
- Followers 2,607
- Likes 0
360 Photos and videos
As EHA2026 comes to a close, what did you enjoy most?
0%
Latest research insights
50%
Meeting colleagues
0%
Novel clinical data
50%
Connecting with leaders
2 votes • 6 days
1
1
39,678
In #CLL improving outcomes means more than controlling disease progression.⁴ Keep the #EHA2026 momentum going and explore this nuanced topic with leading #Hematology expert Prof. Wendtner.
1
153
What motivated you most to join EHA2026 this year?
22%
Latest research insights
22%
Meeting colleagues
24%
Novel clinical data
31%
Connecting with leaders
58 votes • 4 days
1
17
453,249
Welcome to #EHA2026! Are you driven to advance the field of #MalignantHematology? At Lilly, we are committed to revolutionizing #Hematology. Together, we can help transform groundbreaking insights into meaningful outcomes. Follow us for updates from the conference!
1
159
Only 1 more week until #EHA2026 in Stockholm! We look forward to exploring the latest advancements and cutting-edge developments in #hematology. Have you mapped out your conference agenda yet?
2
1,087
2 weeks until #EHA2026, where the global #hematology community meets in person or online. This annual conference is a yearly highlight, with an exceptional scientific program, plenary sessions and symposia. Lilly is proud to support this event as a sponsor. Will you attend?
462
During Mental Health Month, we note mental health challenges are common in hematological malignancies (HM). Yet a study found under half of HCPs believe patients' psychosocial support is adequate. (Brett J, et al. BMJ Open. 2023;13(2):e060106)
Supporting mental wellbeing: Your top recommendation to patients with a HM?
163
Overall survival is the gold standard in #BreastCancer, but is not always the primary trial endpoint.¹,² Listen to an expert explore why alternative endpoints may fall short.¹,² How do you rate endpoints in practice?
1
406
International Nurses Day: Celebrating oncology nurses! Vital in CLL/MCL, they translate complex science into essential daily support for patients & families across the entire cancer journey.
8
2
107
3,443,862
As #ESMOBreast26 wraps up, the conversations move forward.
We’re grateful to everyone who connected with us throughout the congress. Together, we continue helping shape the future of #BreastCancerCare.
Stay connected for our next event!
2
455
In HR /HER2 #EarlyBreastCancer, multiple factors are considered together to estimate the #RiskOfRecurrence.
Nodal status remains one of the key determinants, with additional factors further contributing to risk stratification.
3
858
In #EBC, even modest improvements in overall survival can represent practice changing absolute benefit across large patient populations.¹,²
A 2015 meta-analysis reported a 2.1% absolute 10-year overall survival benefit with aromatase inhibitors vs tamoxifen.²
#ESMOBreast26
1
663
When stratifying patients by risk of recurrence, which factor most influences your clinical decision-making?
Vote below.
23%
Nodal involvement
25%
Tumor grade
20%
21-gene assay
31%
Biomarkers of progression
605 votes • Final results
6
5
55
3,195,235
#ESMOBreast26 begins today!
As conversations around innovation and cancer care evolution take center stage, we invite you to visit the Lilly booth to engage with our team and join the dialogue shaping #BreastCancerCare.
See you there.
1
2
310
Many people with a haematological malignancy face a long, emotionally taxing journey.¹,² This Mental Health Month, let's recognize that comprehensive care includes mental health support. Build in routine check-ins and link patients to psychosocial resources.
8
6
50
2,853,491
Continuing prescribed endocrine therapy is critical in #BreastCancer. Poor adherence or early discontinuation is linked to higher relapse risk and lower survival. How are you helping patients stay on treatment?
1
1
187
How important is overall survival in #EarlyBreastCancer?
Overall survival plays a central role in shaping treatment decisions and defining meaningful outcomes in curative settings.
Follow us for more on #ESMOBreast26.
1
1
227